Affiliation: National Institutes of Health
- Trend tests for case-control studies of genetic markers: power, sample size and robustnessB Freidlin
Biometric Research Branch, National Cancer Institute, Rockville, MD 20892, USA
Hum Hered 53:146-52. 2002..Simulation results of the robustness of these two tests indicate that the more computationally involved MAX test is preferable...
- Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxinsM A Smith
National Cancer Institute, Bethesda, MD 20892, USA
J Clin Oncol 17:569-77. 1999..The Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) has developed a monitoring plan to obtain reliable estimates of the risk of secondary leukemia after epipodophyllotoxin treatment...
- Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemiasB D Cheson
The Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
J Clin Oncol 17:2454-60. 1999..The purpose of the present study was to assess the frequency of second tumors in patients with CLL who are treated with fludarabine and in patients with HCL who are treated with DCF and CdA...
- Robust TDT-type candidate-gene association testsG Zheng
National Heart Lung and Blood Institute, Bethesda, MD 20892, USA
Ann Hum Genet 66:145-55. 2002..g. dominant through additive) a simple linear combination also performs well. In general, the MAX has better power properties than the TDT for the study of candidate genes when the mode of inheritance is unknown...
- Efficiency robust tests for survival or ordered categorical dataB Freidlin
Biometric Research Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
Biometrics 55:883-6. 1999..The second procedure, called the MX, uses the maximum of the optimal statistics. Both approaches yield efficiency robust procedures for survival analysis and ordinal categorical data. Guidelines for choosing between them are provided...
- Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseasesK G Becker
Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 95:9979-84. 1998..This nonrandom clustering supports a hypothesis that, in some cases, clinically distinct autoimmune diseases may be controlled by a common set of susceptibility genes...
- On power and efficiency robust linkage tests for affected sibsJ L Gastwirth
Division of Cancer Genetics and Epidemiology, National Cancer Institute, Bethesda, MD 20892, USA
Ann Hum Genet 64:443-53. 2000..When the minimal correlation is less than 0.5, an alternate robust procedure is proposed. The methods apply to combining data from sibships of different sizes...
- Trends in reported incidence of primary malignant brain tumors in children in the United StatesM A Smith
Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA
J Natl Cancer Inst 90:1269-77. 1998....
- Assessing causal relationships between treatments and clinical outcomes: always read the fine printB Freidlin
Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Plaza, Bethesda, MD 20892, USA
Bone Marrow Transplant 47:626-32. 2012..At the same time, we illustrate how careful application of special statistical methods for assessment of treatment-outcome causation can be instrumental in complementing existing randomized evidence and guiding design of future research...
- Unconditional versions of several tests commonly used in the analysis of contingency tablesB Freidlin
Biometric Research Branch, National Cancer Institute, Bethesda, Maryland 20892 7434, USA
Biometrics 55:264-7. 1999..The unconditional procedures are compared to the conditional ones by reanalyzing some published biomedical data...
- Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering resultsO S Breathnach
Lowe Center for Thoracic Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 19:1734-42. 2001..Techniques for improved use of patient resources and appropriate trial design for phase III randomized therapeutic trials with patients with advanced NSCLC need to be developed...